



## Lipedema Treatment

<b>LOB(s):</b> <input checked="" type="checkbox"/> Commercial  <input checked="" type="checkbox"/> Medicare  <input checked="" type="checkbox"/> Medicaid	<b>State(s):</b> <input checked="" type="checkbox"/> Idaho <input checked="" type="checkbox"/> Montana <input checked="" type="checkbox"/> Oregon <input checked="" type="checkbox"/> Washington <input type="checkbox"/> Other:  <input checked="" type="checkbox"/> Oregon <input type="checkbox"/> Washington
--	---

## Enterprise Policy

Clinical Guidelines are written when necessary to provide guidance to providers and members in order to outline and clarify coverage criteria in accordance with the terms of the Member's policy. This Clinical Guideline only applies to PacificSource Health Plans, PacificSource Community Health Plans, and PacificSource Community Solutions in Idaho, Montana, Oregon, and Washington. Because of the changing nature of medicine, this list is subject to revision and update without notice. This document is designed for informational purposes only and is not an authorization or contract. Coverage determinations are made on a case-by-case basis and subject to the terms, conditions, limitations, and exclusions of the Member's policy. Member policies differ in benefits and to the extent a conflict exists between the Clinical Guideline and the Member's policy, the Member's policy language shall control. Clinical Guidelines do not constitute medical advice nor guarantee coverage.

## Background

Lipedema is a painful, chronic, incurable disease that almost exclusively affects women after puberty and is characterized by abnormal bilateral enlargement of subcutaneous adipose tissue of the legs or arms but with normal hands and feet. Symptoms include painful sensation in the involved limbs, impaired mobility, and disfigurement with lumps under the skin.

Treatment for lipedema is focused on managing the symptoms by reducing volume, inflammation, and pain, restoring, or maintaining mobility and slowing disease progression. First line treatment is conservative, including complex decongestive therapy (CDT). CDT combines several approaches including manual lymph drainage, compression therapy, and physical mobilization. When symptoms persist and worsen, surgical options such as lipectomy or liposuction may be considered.

Lipectomy is a surgical technique that involves the surgical removal of excess subcutaneous adipose tissue that accumulates as a result of lipedema.

Liposuction is a surgical procedure performed to recontour the individual's body by removing excess fat deposits that have been resistant to reduction by diet or exercise.

## Criteria

### Commercial

**Prior authorization is required.**

#### **A. Lipectomy/Liposuction**

PacificSource may consider lipectomy and/or liposuction for the treatment of lipedema to be medically necessary when **ALL** of the following criteria is met:

1. Documentation supports significant functional impairment (e.g., difficulty performing activities of daily living) or medical complication (i.e., recurrent cellulitis)
2. When lipectomy and/or liposuction is expected to improve the functional impairment
3. Condition has failed to respond to at least 3 consecutive months of medical management (e.g., conservative treatment with compression garments, manual lymph drainage).

## Medicaid

PacificSource Community Solutions follows Oregon Administrative Rules (OARs) 410-120-1200 and 410-141-3820 through 3830 for coverage of Lipedema Treatment.

## Medicare

PacificSource Medicare follows Local Coverage Determination for Plastic Surgery L37020

## Coding Information

---

The following list of codes are for informational purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

- 15832 Excision, excessive skin, and subcutaneous tissue (includes lipectomy); thigh
- 15833 Excision, excessive skin, and subcutaneous tissue (includes lipectomy); leg
- 15834 Excision, excessive skin, and subcutaneous tissue (includes lipectomy); hip
- 15835 Excision, excessive skin, and subcutaneous tissue (includes lipectomy); buttock
- 15836 Excision, excessive skin, and subcutaneous tissue (includes lipectomy); arm
- 15837 Excision, excessive skin, and subcutaneous tissue (includes lipectomy); forearm or hand
- 15839 Excision, excessive skin, and subcutaneous tissue (includes lipectomy), other area
- 15877 Suction assisted lipectomy; trunk
- 15878 Suction assisted lipectomy; upper extremity
- 15879 Suction assisted lipectomy; lower extremity

CPT® codes, descriptions and materials are copyrighted by the American Medical Association (AMA).

HCPCS® codes, descriptions and materials are copyrighted by Centers for Medicare and Medicaid Services (CMS).

## Definitions

---

**Cellulitis:** An infection that spreads to deep tissues of the skin and muscle, which may cause warmth, tenderness, fever, chills, swollen lymph nodes, and blisters.

**Functional/Physical Impairment:** An impairment which causes deviation from the normal function of a tissue or organ resulting in a significantly limited, impaired, or delayed capacity to move, coordinate actions, or perform physical activities.

**Lipedema:** A chronic disease affecting almost exclusively women after puberty, characterized by painful abnormal enlargement of subcutaneous adipose tissue of the arms and legs.

**Lipectomy:** the surgical removal of fatty tissue.

**Liposuction:** a technique in surgery for removing excess fat from under the skin by suction.

## References

---

Bauer, A. T., von Lukowicz, D., Lossagk, K., Aitzetmueller, M., Moog, P., Cerny, M., Erne, H., Schmauss, D., Duscher, D., & Machens, H. G. (2019). New Insights on Lipedema: The Enigmatic Disease of the Peripheral Fat. *Plastic and reconstructive surgery*, 144(6), 1475–1484.

<https://doi.org/10.1097/PRS.00000000000006280>

Dadras, M., Mallinger, P. J., Corterier, C. C., Theodosiadi, S., & Ghods, M. (2017). Liposuction in the Treatment of Lipedema: A Longitudinal Study. *Archives of plastic surgery*, 44(4), 324–331.

<https://doi.org/10.5999/aps.2017.44.4.324>

Halk, A. B., & Damstra, R. J. (2017). First Dutch guidelines on lipedema using the international classification of functioning, disability, and health. *Phlebology*, 32(3), 152–159.

<https://doi.org/10.1177/0268355516639421>

Lamprou, D. A., Voesten, H. G., Damstra, R. J., & Wikkeling, O. R. (2017). Circumferential suction-assisted lipectomy in the treatment of primary and secondary end-stage lymphoedema of the leg. *The British journal of surgery*, 104(1), 84–89. <https://doi.org/10.1002/bjs.10325>

National Institutes of Health. (February 12, 2021). National Center for advancing translational sciences. Lipedema. Available at: <https://rarediseases.info.nih.gov/diseases/10542/lipedema>.

National Lymphedema Network (NLN). National Lymphedema position papers. Available at: <https://lymphnet.org/position-papers/>.

Peprah, K., & MacDougall, D. (2019). *Liposuction for the Treatment of Lipedema: A Review of Clinical Effectiveness and Guidelines*. Canadian Agency for Drugs and Technologies in Health.

Witte, T., Dadras, M., Heck, F. C., Heck, M., Habermalz, B., Welss, S., Lehnhardt, M., & Behr, B. (2020). Water-jet-assisted liposuction for the treatment of lipedema: Standardized treatment protocol and results of 63 patients. *Journal of plastic, reconstructive & aesthetic surgery : JPRAS*, 73(9), 1637–1644. <https://doi.org/10.1016/j.bjps.2020.03.002>

Wollina, U., & Heinig, B. (2019). Treatment of lipedema by low-volume micro-cannular liposuction in tumescent anesthesia: Results in 111 patients. *Dermatologic therapy*, 32(2), e12820.

<https://doi.org/10.1111/dth.12820>

## Appendix

---

**Policy Number:**

**Effective:** 11/01/2022

**Next review:** 11/1/2024

**Policy type:** Enterprise

**Author(s):**

**Depts:** Health Services

**Applicable regulation(s):** OARs 410-120-1200 and 410-141-3820 through 3830

**Commercial Ops:** 12/2023

**Government Ops:** 12/2023